SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001479290-21-000059
Filing Date
2021-03-02
Accepted
2021-03-02 20:12:38
Documents
2
Period of Report
2021-03-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_161473394199083.html 3  
1 FORM 3 wf-form3_161473394199083.xml 3 1700
2 KOLAJA POA ex-24.htm EX-24 3713
  Complete submission text file 0001479290-21-000059.txt   6813
Mailing Address 7555 GATEWAY BLVD NEWARK CA 94560
Business Address 1222 DEMONBREUN STREET SUITE 1001 NASHVILLE TN 37203 510-742-3400
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O REVANCE THERAPEUTICS, INC 1222 DEMONBREUN STREET, SUITE 1001 NASHVILLE TN 37203
Business Address
Kolaja Carey OConnor (Reporting) CIK: 0001848717 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36297 | Film No.: 21706470